Clinical trials: Anti-Xa Activity
Anticoagulants and Bleeding Disorders, Surgery
Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin
The main objective of this study is to determine the time interval following the last treatment dose of enoxaparin at which the amount of anti-Xa level activity is reliably less than 0.2 international unit per milliliter (IU/mL)…
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
- Trial name
- NCT03296033
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Wake Forest University Health Sciences
Anticoagulants and Bleeding Disorders
Comparison of Heparin Anti-Xa Activity From Central Venous Catheter Samples Using a 5 mL Syringe Flush or a Vacuum Tube Flush Versus Peripheral Vein Samples in ICU Patients
The goal is to investigate whether blood samples drawn from a central venous catheter can provide reliable measurements of unfractionated heparin (UFH) anti-Xa activity, compared to the standard method of peripheral vein…
- Trial name
- CASSANDRA (NCT07183605)
- Testing
- catheter flushing techniques
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Venous Thromboembolism, Obese Patients
Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.
To evaluate appropriateness of enoxaparin bioavailability at two different sites of subcutaneous administration (arms or abdomen) in primary or secondary prevention of thromboembolism in a population of patients with severe…
- Trial name
- EPOS (NCT07213713)
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Venous Thromboembolic Disease
Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy
The Quantra(r) hemostasis analyzer (Stago) is a recent addition to the family of global hemostasis tests. It uses ultrasound-based technology to characterize the viscoelastic properties of a whole blood sample during coagulation.
- Trial name
- QuantiXa (NCT05993533)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis
Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.
Dose of anticoagulant prophylaxis in patients with continuous veno-venous hemodiafiltration may be insufficient to keep anti-Xa factor activity in prophylactic range.
- Trial name
- NCT04671160
- Testing
- Assessment the activity of anti-Xa factor.
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Gdansk
Myocardial Infarction, Venous Thromboembolism
Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring
Background: Unfractionated heparin (UFH) is a sulfated polysaccharide extracted from porcine intestinal mucosa that enhances the inhibitory activity of the natural anticoagulant antithrombin towards most activated clotting…
- Conditions
- Myocardial Infarction, Venous Thromboembolism, Stroke, Bleeding
- Trial name
- CATCH (NCT03426982)
- Testing
- Unfractionated heparin
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Wuhan Asia Heart Hospital
Pediatric Kidney Transplant Recipients
Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)
Allograft vascular thrombosis is a devastating complication in kidney transplantation in adults and older children. Though uncommon, it is often irreversible and represents the main cause of graft loss within after kidney…
- Trial name
- OPTI-TREX (NCT05672550)
- Testing
- Bayesian based dose adjustment of enoxaparin, Usual dose adjustment of enoxaparin
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neoplasm, Venous Thromboembolism
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous dalteparin in patients with cancer associated thrombosis.
- Trial name
- CASTA-DIVA (NCT02746185)
- Testing
- rivaroxaban, Low-molecular-weight heparin
- Where
- 15 sites in France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anti-Xa Activity
A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma
This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in participants taking apixaban 2.5 mg twice a day by mouth (PO BID).
- Trial name
- ADAM (NCT02749617)
- Testing
- apixaban
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of British Columbia
Thromboembolic Disease
HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT
Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) provide anticoagulation through their anti-Xa and anti-IIa activity.
- Trial name
- HIMA (NCT07302620)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Strasbourg, France
Neoplasms, Venous Thromboembolism
Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism
Low molecular weight heparins (LMWH) are the reference molecule for the long term treatment of venous thromboembolism (VTE) in cancer patients but remains, however, associated with a high risk of recurrent thromboembolism.
- Trial name
- aXa (NCT02898051)
- Where
- 8 sites in France
- Volunteers
- 370 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aortic Diseases, Arterial Disease
Correlation Between LR-ACT and Anti Xa Activity During Endovascular Surgery Procedures. AXAES (Anti Xa vs ACT-LR in Endovascular Surgery)
Activated clotting time (ACT) is currently recommended to monitor high concentrations heparin anticoagulation. ACT-LR was specifically designed to measure the activity of low dose of heparin used during endovascular surgery.
- Conditions
- Aortic Diseases, Arterial Disease, Thrombosis
- Trial name
- AXAES (NCT05554055)
- Testing
- Anti Xa activity measurement.
- Where
- France
- Sponsor
- Hospices Civils de Lyon
Morbid Obesity, Thromboembolism
Prophylaxis of Venous Thromboembolism After Bariatric Surgery
This study is a prospective evaluation of the relationship between lean body weight and anti-Xa activity and 5700 International Units (IU) nadroparin 4 hours after subcutaneous administration in morbidly obese patients after…
- Conditions
- Morbid Obesity, Thromboembolism, Bypass Complications
- Trial name
- NCT02295150
- Testing
- Nadroparin
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Rijnstate Hospital
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Atrial Fibrillation
Specific Anti Factor Xa Activity Dosage to Enhance Detection of Nonadherence in Atrial Fibrillation Patients
Direct oral anticoagulants (DOAC), an inhibitor of factor IIa (dabigatran) or factor Xa inhibitors (rivaroxaban, apixaban) are an alternative to treatment with warfarin in patients with atrial fibrillation (AF) non-valvular .
- Trial name
- NCT02925247
- Testing
- Adherence to oral anticoagulant treatment
- Volunteers
- 150 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Deep Venous Thrombosis
Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs
The three purposes of this study are the following: To compare during a 6-month treatment the safety and effectiveness of idrabiotaparinux (SSR126517) with that of idraparinux (SR34006), taking into account new events of deep…
- Trial name
- EQUINOX (NCT00311090)
- Testing
- Idrabiotaparinux sodium, Idraparinux sodium, Avidin
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 757 people
- Sponsor
- Sanofi
Patients Receiving Rivaroxaban Treatment
Validation of Rivaroxaban Assay for US Registration
The objective of the study is to demonstrate the performances of the STA® - Rivaroxaban Calibrator and STA® - Rivaroxaban Control in combination with the STA® - Liquid Anti-Xa to determine the quantity of rivaroxaban in plasma…
- Trial name
- NCT02333929
- Testing
- STA- Rivaroxaban Calibrator&Control
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Diagnostica Stago